Loading...
Docoh

Homology Medicines (FIXX)

Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology's proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its family of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

FIXX stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$4.55
Low target
$2.10
High target
$7.00
Credit Suisse
Maintains
Neutral
$2.10
17 May 22
Canaccord Genuity
Maintains
Buy
$7.00
6 Apr 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 22
26 Jun 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 248.4M 248.4M 248.4M 248.4M 248.4M 248.4M
Cash burn (monthly) (no burn) (no burn) (no burn) 97.92K 10.23M 9.22M
Cash used (since last report) n/a n/a n/a 281.16K 29.37M 26.47M
Cash remaining n/a n/a n/a 248.12M 219.03M 221.93M
Runway (months of cash) n/a n/a n/a 2534.0 21.4 24.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 22 Parmar Kush Option Common Stock Grant Acquire A No No 1.88 18,000 33.84K 18,000
15 Jun 22 Gregory Richard J. Option Common Stock Grant Acquire A No No 1.88 18,000 33.84K 18,000
15 Jun 22 Patterson Matthew R Option Common Stock Grant Acquire A No No 1.88 18,000 33.84K 18,000
15 Jun 22 Steven Gillis Option Common Stock Grant Acquire A No No 1.88 18,000 33.84K 18,000
15 Jun 22 Thistle Mary Option Common Stock Grant Acquire A No No 1.88 18,000 33.84K 18,000
66.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 106 122 -13.1%
Opened positions 10 21 -52.4%
Closed positions 26 20 +30.0%
Increased positions 25 40 -37.5%
Reduced positions 38 30 +26.7%
13F shares Current Prev Q Change
Total value 186.97M 649.28M -71.2%
Total shares 38.37M 42.9M -10.6%
Total puts 93.9K 85.3K +10.1%
Total calls 22.8K 205K -88.9%
Total put/call ratio 4.1 0.4 +889.8%
Largest owners Shares Value Change
Temasek 5.65M $17.18M 0.0%
PFE Pfizer 5M $48.05M 0.0%
5AM Ventures IV 4.54M $51.21M 0.0%
5AM Venture Management 4.54M $13.79M 0.0%
BLK Blackrock 3.87M $11.77M +7.9%
Vanguard 1.78M $5.42M -8.7%
BLVGF Bellevue 1.65M $5.01M -5.2%
STT State Street 990.91K $3.01M +17.1%
FMR 856.44K $2.6M -31.7%
Vivo Capital 853.14K $2.59M 0.0%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 69.64K -2.23M -97.0%
Woodline Partners 0 -967.07K EXIT
Wellington Management 0 -607.97K EXIT
FMR 856.44K -396.65K -31.7%
Jacobs Levy Equity Management 477.64K -357.26K -42.8%
GS Goldman Sachs 371.84K -286.97K -43.6%
BLK Blackrock 3.87M +282.17K +7.9%
Citadel Advisors 435.77K +226.59K +108.3%
Tang Capital Management 214.9K +214.9K NEW
Millennium Management 0 -209.17K EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: absorbed, advice, aforementioned, aimed, ancillary, anesthesiologist, anxiety, appraisal, assumption, ATMP, backup, bankruptcy, Biomedica, borderline, built, cal, caption, cardiac, carrier, certified, circumvent, CJEU, classical, CMO, Commissioner, conflict, constitute, contrary, core, Council, crucial, CTA, currency, CV, dampening, deceptive, deconsolidation, derecognized, detachable, dialogue, discharge, dissemination, diverge, dorsal, DRG, effort, eighteen, elevated, embedded, ERT, facilitate, footage, forecasted, forensic, formation, formatted, framework, FTC, ganglion, goodwill, half, harder, hearing, ILAP, immune, immunosuppressive, improbable, inclusion, inflation, inhibitor, Inline, insolvency, instability, invasive, investee, issuable, jointly, Justice, Kelly, lab, laid, largest, lawfully, lawsuit, leasehold, letter, Linkbase, longevity, main, malware, manipulated, marker, maximum, memo, MHRA, Michael, migrated, mislabeling, missing, mobility, motion, noncontrolling, nurse, obfuscate, obligor, occupied, online, opposed, OXB, Oxford, Page, pain, painful, Parent, Parliament, Passage, passport, perspective, phishing, physical, Pizzuto, placebo, plc, Portability, post, proceed, prophylactic, proportional, proportionality, proportionate, proven, Qualitative, radiographic, ransomware, rapporteur, reframing, regenerate, regime, regimen, remeasured, renewed, representation, repurposed, reserved, residual, restart, Roadrunner, root, run, Russia, Russian, safest, Schema, segregation, settlement, Shield, shorter, skilled, slightly, Solution, speed, stake, steroid, streamline, substance, suggest, supervisory, surveyed, Taxonomy, territory, thought, threat, threshold, Tim, timeframe, title, tyrosine, Ukraine, uncured, undergoing, unfair, unfounded, unspecified, upfront, verity, watched, weekly, whichever, window, XBRL
Removed: accepting, Asia, automatically, bioreactor, calculate, capsid, characterization, clarifying, deep, disposed, driven, improving, incurrence, involuntarily, justify, library, medium, monoclonal, optionee, outsourcing, participating, performed, preempted, producing, ranging, rarity, represented, repurchase, resume, resumption, retrospective, safeguarding, satisfying, shareholder, sourcing, subcommittee, summary, understanding, unsatisfied, versatile, visiting, weighted, worker

Patents

Utility
Gene Therapy Methods
26 May 22
Provided are methods for reducing the risk of occurrence and/or the severity of transaminitis in a subject that is receiving a gene therapy.
Utility
Gene Therapy Methods
26 May 22
Provided are methods for reducing the risk of occurrence and/or the severity of pathogenic diseases (e.g., diseases associate with varicella zoster virus reactivation, influenza infection, and/or S. pneumoniae infection) in a subject that is receiving a gene therapy and an accompanying immunosuppressant regimen.
Utility
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
19 Apr 22
Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease.
Utility
Adeno-associated Virus Compositions for Restoring Pah Gene Function and Methods of Use Thereof
23 Dec 21
Provided herein are recombinant adeno-associated virus (rAAV) compositions that can restore phenylalanine hydroxylase (PAH) gene function in cells, and methods for using the same to treat diseases associated with reduction of PAH gene function (e.g., PKU).
Utility
Adeno-associated Virus Compositions for Ids Gene Transfer and Methods of Use Thereof
25 Nov 21
Provided are adeno-associated virus (AAV) compositions that can restore IDS gene function in cells, and methods for using the these AAV compositions to treat disorders associated with reduction of IDS gene function (e.g., Hunter syndrome).